A testing package can be a convenient way to screen for more than one infection, but the best choice is not always the largest panel. A useful plan starts with the question you need answered: routine screening, a new symptom, a recent exposure, a partner’s diagnosis or reassurance before a new relationship.

Package or individual test?

A package can be appropriate when you want broader screening or when several infections are relevant to your circumstances. Individual tests may be more useful when there is a specific exposure, symptom or follow-up question. The right answer can also involve a combination of testing now and a later follow-up test because detection windows vary.

Sample type is part of the decision

Some infections are commonly assessed with blood samples, while others may use urine or swabs. A broad package does not automatically cover every relevant site of contact. Tell the clinician what happened so they can explain whether a different sample or targeted test is worth considering.

Do not let a package replace a conversation

Privacy matters, but clear information matters too. A short confidential discussion can help prevent false reassurance from testing too early or choosing a test that does not match the concern. It can also help you understand what a result means and when a follow-up might be sensible.

A simple way to prepare

Before booking, note the dates of any possible exposure, symptoms, previous STI history, recent medication and the tests you are considering. You do not need to decide alone; those notes give the clinic a practical starting point for personalised advice.

Further reading: Clinical information from CDC or WHO. This guide is general information and does not replace an individual medical assessment.

Herpes and HPV are often grouped into general STI questions, but testing for each is more individual than many people expect. The best next step depends on symptoms, anatomy, previous screening and the question you want the test to answer.

Herpes testing is most useful in context

When a new sore or blister is present, a clinician may be able to take a sample from the affected area. Blood tests can sometimes show exposure to herpes viruses, but they do not always explain the timing of infection, the site involved or whether a current symptom is caused by herpes. A consultation helps set realistic expectations before testing.

HPV testing is not one universal test

HPV testing is commonly used in cervical screening contexts and is not routinely used as a general screening test for every person or every body site. The appropriate screening approach depends on anatomy, age, screening history, symptoms and local clinical guidance.

Symptoms should be assessed promptly

New sores, unusual growths, bleeding, persistent itching or pain deserve a clinical assessment. They may have causes other than herpes or HPV, and self-diagnosis from photographs or online descriptions is unreliable.

Questions to bring to a consultation

Tell the clinician about symptoms, when they began, previous test or screening results, vaccination history and any recent exposure that concerns you. You can then decide together whether testing, examination, screening or follow-up is the most useful next step.

Read about herpes testing and HPV testing in Phuket.

Further reading: Clinical information from CDC or WHO. This guide is general information and does not replace an individual medical assessment.

Hepatitis B and hepatitis C affect the liver, but they are caused by different viruses and are assessed differently. Screening can be part of sexual health care, particularly when a person wants a fuller picture after a relevant exposure or has never discussed their hepatitis status with a clinician.

Hepatitis B: infection, immunity and vaccination

Hepatitis B testing can help a clinician understand whether there is current infection, past infection or protection from vaccination. The meaning of a result often depends on more than one blood marker, so it is important to have results explained rather than relying on a single label.

Hepatitis C: a different testing pathway

Hepatitis C screening typically begins with an antibody test. When an antibody result is reactive, further testing may be used to determine whether there is a current infection. The clinic can advise which test is relevant for your circumstances and whether follow-up is needed.

Who may want to ask about screening?

It can be useful to discuss screening after blood exposure, sharing injection equipment, certain sexual exposures, a previous diagnosis, or where vaccination and prior testing history are unclear. Pregnancy, liver symptoms and existing health conditions can also change what is appropriate, so mention them in your consultation.

Keep the discussion practical

Bring any previous records if available, including hepatitis B vaccination history and earlier test results. This gives the clinician a more complete starting point and may prevent unnecessary repetition.

See the individual pages for hepatitis B testing and hepatitis C testing.

Further reading: Clinical information from CDC or WHO. This guide is general information and does not replace an individual medical assessment.

It is common to ask for “an STI test,” but the most useful testing plan depends on what you are trying to rule out. Syphilis, chlamydia and gonorrhoea are different infections, and the relevant test can depend on timing, symptoms and the sites of contact.

Syphilis is commonly assessed with blood tests

Syphilis testing often begins with a blood sample. A clinician may interpret screening and confirmatory results together, because a single reactive screening result is not always the final diagnosis. Let the clinic know about previous syphilis treatment or prior test results, as this may affect how results are understood.

Chlamydia and gonorrhoea may need urine or swab samples

For chlamydia and gonorrhoea, the sample type can matter. Depending on the exposure, a urine sample or swab from a relevant site may be considered. A test from only one site may not answer questions about another site of contact, which is why a straightforward, factual history helps.

Symptoms are only part of the picture

Some people have discharge, pain when urinating, sores, rash or throat symptoms. Others have no symptoms at all. Symptoms can have many causes, so they are a reason to seek assessment rather than a reliable way to identify an infection on your own.

Timing and treatment matter

A recent exposure can require a plan for testing now and possibly testing later. Avoid self-starting antibiotics before your appointment unless a clinician has advised them, because they can affect testing and treatment decisions.

Learn more about chlamydia testing and gonorrhoea testing in Phuket.

Further reading: Clinical information from CDC or WHO. This guide is general information and does not replace an individual medical assessment.

PrEP and PEP are both HIV prevention medicines, but they solve different problems. The simplest distinction is timing: PrEP is planned prevention before possible future exposure, while PEP is urgent prevention after a recent possible exposure.

PrEP is for ongoing prevention

PrEP, or pre-exposure prophylaxis, is for people who do not have HIV and may have future exposure through sex or injection drug use. Before starting, a clinician confirms HIV-negative status and considers the right testing and follow-up plan. PrEP should be taken exactly as prescribed, with regular clinical reviews.

PrEP reduces the chance of acquiring HIV, but it does not protect against every sexually transmitted infection or pregnancy. Condoms and regular STI screening can remain important parts of a wider sexual health plan.

PEP is for an emergency window

PEP, or post-exposure prophylaxis, is considered after a recent possible exposure and must be started within 72 hours when appropriate. It is a short, time-sensitive course, not a replacement for longer-term prevention when exposures may happen repeatedly.

Moving from PEP to PrEP

For someone who has needed PEP more than once or expects ongoing risk, a clinician may discuss transitioning to PrEP after the PEP course and follow-up testing. This is a useful conversation, not a judgement about anyone’s choices.

Ask for a plan that fits your life

The right approach depends on your health history, current medicines, testing status and the kind of prevention you can use consistently. A confidential consultation is the right setting to talk through those details.

Further reading: Clinical information from CDC or WHO. This guide is general information and does not replace an individual medical assessment.

PEP stands for post-exposure prophylaxis. It is a short course of HIV medicines used after a possible exposure, when a clinician decides it is appropriate. It is time-sensitive: PEP needs to be started within 72 hours, and sooner is better.

When to seek an urgent assessment

Contact a clinician promptly after a possible exposure involving sex, shared injection equipment, sexual assault or another situation where HIV could be transmitted. The clinician will assess the details of the exposure, not simply the word “exposure.” They may ask about the timing, body sites involved, barrier use, known information about the other person and your current medications.

PEP is not the same as an HIV test

Testing is part of PEP care, but a test cannot replace a timely PEP assessment in the first 72 hours. If PEP is prescribed, it is usually taken daily for 28 days, with follow-up arranged by the treating clinician. Testing may also be repeated at recommended intervals.

What if more than 72 hours have passed?

PEP is generally not recommended after that window. Testing, tailored follow-up and a discussion about future prevention can still be useful. A clinician can help you understand the relevant testing timeline and whether PrEP may be a better ongoing option.

Prepare a short timeline

Write down the date and time, what happened, any condom or barrier use, and whether there have been other recent exposures. This makes an urgent conversation easier and helps the clinician make a prompt, informed decision.

Further reading: Clinical information from CDC or WHO. This guide is general information and does not replace an individual medical assessment.

After a possible HIV exposure, timing can feel like the hardest part. A test can give valuable information, but no HIV test detects infection immediately. The time between an exposure and the point when a particular test can detect HIV is called its window period.

Why the type of HIV test matters

Different tests look for different markers. Nucleic acid tests look for HIV genetic material. Antigen/antibody tests look for p24 antigen and antibodies. Antibody-only tests look for the body’s immune response. Each approach has a different detection range, which is why a clinician will consider both the date of a possible exposure and the test available.

As a general guide, CDC notes that a laboratory antigen/antibody test using blood from a vein can usually detect HIV about 18 to 45 days after exposure. Rapid antigen/antibody and antibody tests can have longer windows. These ranges are not a substitute for individual advice, especially where there have been multiple exposures or symptoms.

A negative result can still need follow-up

A negative test result is reassuring only in the context of its timing. If a test was taken before that test’s window period has passed, a clinician may recommend another test later. That is not because the first result is meaningless; it is because follow-up is the clearest way to answer the question for the relevant date.

What to tell the clinic

When asking about testing, share the approximate date or dates, the type of contact, whether barriers were used, any symptoms and previous test results. Those details help the clinic discuss a focused plan instead of suggesting a one-size-fits-all panel.

When to seek time-sensitive help

If a possible exposure was within the past 72 hours, do not wait for a future testing date before asking about PEP. PEP is an emergency HIV prevention option that must be started promptly when appropriate.

Further reading: Clinical information from CDC or WHO. This guide is general information and does not replace an individual medical assessment.